Altimmune's (ALT) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Altimmune's stock rating was reiterated as a "sell (D-)" by Weiss Ratings, indicating ongoing concerns about the company's performance.
• Despite varied analyses from other firms, the consensus rating for Altimmune remains at a "Hold" with a target price of $17.40.
• Altimmune reported a quarterly earnings loss of ($0.27) per share, surpassing analysts' expectations but still reflecting a negative growth trend.

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group raised Altimmune to a "strong sell" rating in a report on Thursday, July 10th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Altimmune in a report on Wednesday, August 13th. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. JMP Securities lowered their price objective on Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a research report on Thursday, July 10th. Finally, Wall Street Zen upgraded Altimmune from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $17.40.

Altimmune Stock Performance

Shares of NASDAQ:ALT remained flat at $3.93 during midday trading on Wednesday. The stock had a trading volume of 7,843,327 shares, compared to its average volume of 3,590,219. The stock has a fifty day moving average of $3.70 and a 200 day moving average of $4.65. Altimmune has a 12 month low of $2.90 and a 12 month high of $11.16. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $346.86 million, a price-to-earnings ratio of -3.33 and a beta of 0.07.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, research analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Institutional Trading of Altimmune

Several institutional investors have recently made changes to their positions in ALT. Geode Capital Management LLC lifted its holdings in shares of Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company's stock valued at $7,489,000 after acquiring an additional 228,995 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Altimmune by 387.7% during the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock worth $3,543,000 after acquiring an additional 727,731 shares during the period. Bank of America Corp DE increased its holdings in Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock valued at $2,771,000 after buying an additional 435,467 shares during the period. Beirne Wealth Consulting Services LLC increased its holdings in Altimmune by 16.3% during the second quarter. Beirne Wealth Consulting Services LLC now owns 342,458 shares of the company's stock valued at $1,325,000 after buying an additional 48,000 shares during the period. Finally, Nuveen LLC acquired a new stake in Altimmune in the first quarter valued at approximately $1,304,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.